Jung Won Shin
Jung Won is a reporter based in Seoul covering South Korea, most recently working for PharmAsia News. Her work covers corporate activities in the South Korean pharma/biotech sector as well as government policy and regulatory news. In her role, Jung Won focuses on R&D strategies, clinical development, licensing deals and other major corporate deals and activities in the country's pharma/biotech sector as well as major government measures or regulatory activities in the sector.
Prior to joining Informa, Jung Won worked for Dow Jones Newswires in Seoul, covering stories in various industries and government. Outside of work, she likes to travel and spend time with her family and friends.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Jung Won Shin
Korean Pharma Highlights R&D Progress, 2020 Strategy At JPM
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
Asia Deal Watch: BeiGene Gets Chinese Rights To Two EUSA Rare Disease Therapies
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
Korea 2020 Outlook: Hopes Of Turnaround Amid Potential Deals, Biosimilar Launches, Biologics Law
After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.
Asia Deal Watch: BeiGene Leaps Into New Year By Licensing DKK1 Antibody Candidate
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.
Key Words For Korean Pharma In 2010s: Novelty, Open Innovation, Global Markets
From being generics-focused to becoming innovators and leaders in biosimilars, Scrip takes a look at how the Korean pharma sector and environment have evolved over the past 10 years.
Korea 2019 Review: Industry Spooked By Invossa Affair, Disappointing Trials But Hopes Intact
The South Korean pharma/biotech industry suffered a series of negative blows in 2019 but there were still notable achievements including major drug approvals and large-scale licensing deals.